Israel Active

Israel’s Itamar Medical (reported previously) is funding a trial of its disposable WatchPAT ONE CPAP device. It will be given to 200 confirmed or suspected COVID-19 patients in the Mount Sinai Health (US) system with respiratory symptoms but who do not require hospital admission.

Israel’s Zebra Medical was being deployed last year to detect TB cases across India. Zebra is now assisting Apollo (India’s largest hospital group) to diagnose coronavirus cases using its machine-learning algorithm that analyzes CT scans of suspected Covid-19 infected patients.

Israel’s Respinova developed Pulsehaler to help COPD patients improve their lungs and avoid ventilation. Repinova is now preparing for clinical trials in Israel on patients suffering from acute respiratory distress syndrome (ARDS) as caused by Covid-19.

In animal tests, Israel’s Institute for Biological Research has found two treatments for the genetic disorder Gaucher’s disease are also effective against Covid-19 and other viruses (e.g. West Nile). Cerdelga is already approved for Gaucher’s and Venglustat may be fast-tracked.

HealthSpace 2030, Israel’s high-tech Intensive Care Unit of the future was unveiled in Sheba hospital. 11 technologies integrate augmented reality, communication, monitoring, AI, sensing, and robotic technologies to maximize care and comfort while minimizing risk to staff.

Israel’s Beyond Air develops LungFit  - a revolutionary Nitric Oxide (NO) generator and delivery system. The US FDA and Health Canada have approved the use of LungFit in COVID-19 treatment trials in both countries.

Israeli biotech Kamada has partnered Italy’s Kedrion to develop a human plasma-derived Anti-SARs-COV-2 product. Kamada will use its proprietary IgG platform technology and Kedrion will provide plasma from donors who have recovered from the virus.

Israel’s G Medical has received Emergency Use Authorization from the US FDA for its Vital  Signs Monitoring System (VSMS) ECG Patch. It can be used to monitor Covid-19 patients whose treatment includes medication that may cause life-threatening arrhythmias.

Israel’s DreaMed Diabetes (reported previously) is integrating its Advisor Pro software at Texas Children's Hospital. It allows diabetic children to be monitored remotely and avoids the risk of them (and their parents / guardians) being infected in hospital with Covid-19.

Israel’s VBL Therapeutics (reported previously) has been awarded a grant of up to $0.9 million by the Israel Innovation Authority.  It will support the Phase 3 study of VBL’s lead candidate VB-111 for the treatment of platinum-resistant ovarian cancer.